Does proximity to or involvement of the aorta effect the dose and fractionation you use for an early stage NSCLC?

In the primary treatment setting I think it's very safe as long as you adhere to the constraints used in RTOG 0813 (105% to 0.03cc) since this would be considered a central tumor. I have never seen a complication from treating the aorta using those constraints in the upfront setting.

Retreatment is...